It’s Time: The Life Raft Group Biomarker Testing Campaign – Precise Diagnosis
It's time to to recognize the value of a more precise diagnosis. GISTer Jon Treder shares his story.
It's time to to recognize the value of a more precise diagnosis. GISTer Jon Treder shares his story.
It's time to fully unleash the power of biomarker testing to support precision oncology - all GIST patients should have biomarker (mutational) testing for the best possible personalized treatment plan.
Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is critical. This video shows the action steps of our It's Time campaign.
Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is critical. This video talks about why it's important.
Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is critical. This video talks about why it's important.
Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is critical. Here is a Resource list for GIST and other cancers.
Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is critical. This video talks about why it's important.
It is time to stop talking and take action to assure patients get tested. The goal of the 'It's Time' campaign is to increase and improve the understanding of biomarker testing in the cancer community and get patients tested.
Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is [...]
In a recent post by Oncology Nursing News, Dr. Gina D'Amato, associate professor and assistant director of Clinical Research at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the evolution of treatment in sarcoma, the use of NGS, and predictive and prognostic biomarkers under investigation in the space.